China Primer: Illicit Fentanyl and China's Role (CRS Report for Congress)
| Release Date |
Revised Feb. 20, 2024 |
| Report Number |
IF10890 |
| Report Type |
In Focus |
| Authors |
Liana W. Rosen, Ricardo Barrios, Susan V. Lawrence |
| Source Agency |
Congressional Research Service |
| Older Revisions |
-
Premium Revised Feb. 13, 2024 (3 pages, $24.95)
add
-
Premium Revised Sept. 28, 2023 (2 pages, $24.95)
add
-
Premium Revised Dec. 8, 2022 (2 pages, $24.95)
add
-
Premium Revised July 18, 2022 (3 pages, $24.95)
add
-
Premium Revised Jan. 29, 2021 (107 pages, $24.95)
add
-
Premium Dec. 21, 2018 (2 pages, $24.95)
add
|
Summary:
Addressing illicit fentanyl in the context of the ongoing
opioid crisis in the United States is a domestic and foreign
policy issue for Congress. In addressing the international
dimension of the problem, policymakers have endeavored
to stop foreign-sourced fentanyl, fentanyl-related
substances (i.e., analogues), and chemical inputs (i.e.,
precursors) from entering the United States. Early in the
U.S. opioid epidemic, the People’s Republic of China
(PRC, or China) was the primary source of illicit fentanyl,
but such direct flows have reportedly ceased. U.S.
counternarcotics policy with regard to China has shifted to
preventing PRC-sourced fentanyl precursors from entering
the U.S.-bound fentanyl supply chain via third countries,
and targeting illicit fentanyl-related financial flows linked
to China. U.S.-PRC cooperation on drug control issues has
been severely strained since 2020.
